On September 07, 2026, Blue Owl Capital Inc (NYSE: OWL) disclosed a significant write-down of its loan exposure to Loparex, a specialty materials manufacturer, reducing the loan value nearly to zero. This development has raised fresh concerns about valuation practices within the $1.8 trillion private credit market. Following the second quarter, Blue Owl’s business development company classified its Loparex exposure as non-accrual, while Moody’s downgraded Loparex’s Probability of Default Rating due to misse ...